KRBP
Kiromic BioPharma, Inc. [KRBP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KRBP Stock Summary
Top 10 Correlated ETFs
KRBP
Top 10 Correlated Stocks
KRBP
In the News
KRBP Financial details
Company Rating
Neutral
Market Cap
3.79M
Income
-21.92M
Revenue
0
Book val./share
-1039.64
Cash/share
365.21
Dividend
-
Dividend %
-
Employees
35
Optionable
No
Shortable
Yes
Earnings
15 Apr 2024
P/E
-0.09
Forward P/E
-
PEG
-0
P/S
-
P/B
-0.48
P/C
0.01
P/FCF
-0.11
Quick Ratio
0.25
Current Ratio
0.34
Debt / Equity
-1.7
LT Debt / Equity
-0.1
-
-
EPS (TTM)
-551.84
EPS next Y
-
EPS next Q
-
EPS this Y
-72.78%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
15090.91%
-
-
-
-
SMA20
50%
SMA50
200%
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-171%
ROE
393%
ROC
6.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.16-8.97
52W High
-
52W Low
-
RSI
50
Rel Volume
0.07
Avg Volume
8.24K
Volume
600
Perf Week
-5.45%
Perf Month
30%
Perf Quarter
1029.94%
Perf Half Y
1168.29%
-
-
-
-
Beta
2.009
-
-
Volatility
0.22%, 0.41%
Prev Close
4%
Price
2.6
Change
4%
KRBP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -29 | -127.86 | -67.4 | -70.12 | -19.09 | |
| Operating cash flow per share | -22.53 | -40.79 | -53.39 | -43.61 | -19.34 | |
| Free cash flow per share | -24.87 | -50.5 | -58.37 | -52.57 | -19.53 | |
| Cash per share | 14.92 | 67.58 | 66.61 | 1.18 | 2.92 | |
| Book value per share | 15.3 | 75.65 | 71.78 | -10.6 | -8.31 | |
| Tangible book value per share | 15.3 | 75.65 | 71.78 | -10.6 | -8.31 | |
| Share holders equity per share | 15.3 | 75.65 | 71.78 | -10.6 | -8.31 | |
| Interest debt per share | 0.17 | 3.14 | 1.23 | 17.59 | 12.47 | |
| Market cap | 44.62M | 38.16M | 17.47M | 2.95M | 954.94K | |
| Enterprise value | 42.69M | 28.48M | -7.43M | 11.72M | 13.29M | |
| P/E ratio | -11.9 | -1.99 | -0.68 | -0.08 | -0.05 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -15.31 | -6.23 | -0.86 | -0.12 | -0.04 | |
| PFCF ratio | -13.87 | -5.03 | -0.79 | -0.1 | -0.04 | |
| P/B Ratio | 22.54 | 3.36 | 0.64 | -0.51 | -0.1 | |
| PTB ratio | 22.54 | 3.36 | 0.64 | -0.51 | -0.1 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -11.8 | -1.5 | 0.3 | -0.4 | -0.67 | |
| EV to operating cash flow | -14.65 | -4.65 | 0.37 | -0.49 | -0.63 | |
| EV to free cash flow | -13.27 | -3.76 | 0.33 | -0.41 | -0.62 | |
| Earnings yield | -0.08 | -0.5 | -1.47 | -12.93 | -21.94 | |
| Free cash flow yield | -0.07 | -0.2 | -1.27 | -9.7 | -22.44 | |
| Debt to equity | 0 | 0.04 | 0.02 | -1.63 | -1.7 | |
| Debt to assets | 0 | 0.04 | 0.01 | 0.79 | 1.28 | |
| Net debt to EBITDA | 0.53 | 0.51 | 1 | -0.3 | -0.62 | |
| Current ratio | 3.03 | 7.32 | 7.94 | 0.13 | 0.22 | |
| Interest coverage | -164.68 | -5.82K | -2.11K | -186.87 | 10.77 | |
| Income quality | 0.78 | 0.32 | 0.79 | 0.68 | 1.01 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.1 | 0.24 | 0.09 | 0.21 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -3.46 | -7.29 | -4.03 | -2.92 | -0.09 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 99.93 | 466.5 | 329.94 | 129.35 | 59.74 | |
| ROIC | -1.88 | -1.62 | -0.93 | -5.93 | -2.5 | |
| Return on tangible assets | -1.41 | -1.5 | -0.83 | -3.19 | -1.72 | |
| Graham Net | 9.79 | 57.81 | 57.69 | -31.4 | -16.48 | |
| Working capital | 1.37M | 9.27M | 23.66M | -11.59M | -15.95M | |
| Tangible asset value | 1.98M | 11.36M | 27.32M | -5.77M | -9.12M | |
| Net current asset value | 1.37M | 9.27M | 23.66M | -16.05M | -16.86M | |
| Invested capital | 0 | 0.04 | 0.02 | -1.63 | -1.7 | |
| Average receivables | 12.15K | 0 | 8.1K | 8.1K | 0 | |
| Average payables | 335.75K | 558.8K | 1.44M | 4.76M | 4.72M | |
| Average inventory | 19.25K | 11.1K | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.9 | -1.69 | -0.94 | 6.61 | 2.3 | |
| Capex per share | -2.34 | -9.7 | -4.98 | -8.96 | -0.19 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -12.96 | -7.18 | -6.42 | -3.52 | -534.72 | |
| Operating cash flow per share | -7.53 | -4.73 | -6.13 | -4.39 | -616.36 | |
| Free cash flow per share | -7.64 | -4.73 | -6.13 | -4.48 | -628.79 | |
| Cash per share | 1.18 | 2.35 | 2.56 | 3.68 | 365.21 | |
| Book value per share | -10.6 | -9.33 | -5.97 | -3.77 | -1.04K | |
| Tangible book value per share | -10.6 | -9.33 | -5.97 | -3.77 | -1.04K | |
| Share holders equity per share | -10.6 | -9.33 | -5.97 | -3.77 | -1.04K | |
| Interest debt per share | 17.57 | 14.22 | 9.9 | 9.9 | 1.84K | |
| Market cap | 2.95M | 3.37M | 2.87M | 345.1K | 7.63K | |
| Enterprise value | 11.72M | 13.28M | 10.27M | 7.32M | 12.35M | |
| P/E ratio | -0.1 | -0.13 | -0.11 | -0.02 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -0.72 | -0.82 | -0.44 | -0.07 | 0 | |
| PFCF ratio | -0.71 | -0.82 | -0.44 | -0.06 | 0 | |
| P/B Ratio | -0.51 | -0.41 | -0.46 | -0.08 | 0 | |
| PTB ratio | -0.51 | -0.41 | -0.46 | -0.08 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -1.84 | -3.09 | -2.5 | -2.29 | -3.52 | |
| EV to operating cash flow | -2.86 | -3.22 | -1.59 | -1.4 | -2.28 | |
| EV to free cash flow | -2.82 | -3.22 | -1.59 | -1.37 | -2.24 | |
| Earnings yield | -2.39 | -1.86 | -2.36 | -12.15 | -614.62 | |
| Free cash flow yield | -1.41 | -1.23 | -2.25 | -15.44 | -722.75 | |
| Debt to equity | -1.63 | -1.47 | -1.61 | -2.53 | -1.7 | |
| Debt to assets | 0.79 | 0.91 | 0.74 | 0.8 | 1.28 | |
| Net debt to EBITDA | -1.38 | -2.31 | -1.8 | -2.18 | -3.52 | |
| Current ratio | 0.13 | 0.18 | 0.25 | 0.34 | 0.22 | |
| Interest coverage | -43.36 | -10.76 | -12.8 | -12.8 | -8.4 | |
| Income quality | 0.58 | 0.78 | 0.96 | 1.25 | 1.15 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0.02 | 0.02 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.1 | 0 | 0 | -0.17 | -0.2 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 55.6 | 38.82 | 29.36 | 17.29 | 3.54K | |
| ROIC | -1.2 | -0.97 | -0.8 | -0.99 | -0.94 | |
| Return on tangible assets | -0.59 | -0.48 | -0.5 | -0.29 | -0.39 | |
| Graham Net | -31.4 | -21.99 | -16.34 | -12.05 | -2.06K | |
| Working capital | -11.59M | -16.34M | -13.99M | -11.71M | -15.95M | |
| Tangible asset value | -5.77M | -8.14M | -6.29M | -4.49M | -9.12M | |
| Net current asset value | -16.05M | -17.73M | -15.22M | -12.78M | -16.86M | |
| Invested capital | -1.63 | -1.47 | -1.61 | -2.53 | -1.7 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 6.9M | 7.73M | 7.39M | 5.43M | 3.19M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 1.22 | 0.77 | 1.07 | 0.93 | 0.51 | |
| Capex per share | -0.11 | 0 | 0 | -0.08 | -12.44 |
KRBP Frequently Asked Questions
What is Kiromic BioPharma, Inc. stock symbol ?
Kiromic BioPharma, Inc. is a US stock , located in Houston of Tx and trading under the symbol KRBP
What is Kiromic BioPharma, Inc. stock quote today ?
Kiromic BioPharma, Inc. stock price is $2.6 today.
Is Kiromic BioPharma, Inc. stock public?
Yes, Kiromic BioPharma, Inc. is a publicly traded company.
Company Profile
- Volume Average 8.24K
- Market Capitalization 3.79M
- Employee 35
- CEO Mr. Brian Hungerford
- Headquarters Houston,TX,US
- IPO Date 2020-10-16
-
Website
https://www.kiromic.com 
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
